Enhanced Neurite Outgrowth of Human Model (NT2) Neurons by Small-Molecule Inhibitors of Rho/ROCK Signaling

Frank Roloff1, Hannah Scheiblich1, Carola Dewitz1, Silke Dempewolf1, Michael Stern1, Gerd Bicker1,2*

1 Division of Cell Biology, University of Veterinary Medicine Hannover, Bischofsholer Damm 15/102, 30173, Hannover, Germany, 2 Center for Systems Neuroscience, Hannover, Germany

* gerd.bicker@tiho-hannover.de

Abstract

Axonal injury in the adult human central nervous system often results in loss of sensation and motor functions. Promoting regeneration of severed axons requires the inactivation of growth inhibitory influences from the tissue environment and stimulation of the neuron intrinsic growth potential. Especially glial cell derived factors, such as chondroitin sulfate proteoglycans, Nogo-A, myelin-associated glycoprotein, and myelin in general, prevent axon regeneration. Most of the glial growth inhibiting factors converge onto the Rho/ROCK signaling pathway in neurons. Although conditions in the injured nervous system are clearly different from those during neurite outgrowth in vitro, here we use a chemical approach to manipulate Rho/ROCK signalling with small-molecule agents to encourage neurite outgrowth in cell culture. The development of therapeutic treatments requires drug testing not only on neurons of experimental animals, but also on human neurons. Using human NT2 model neurons, we demonstrate that the pain reliever Ibuprofen decreases RhoA (Ras homolog gene family, member A GTPase) activation and promotes neurite growth. Inhibition of the downstream effector Rho kinase by the drug Y-27632 results in a strong increase in neurite outgrowth. Conversely, activation of the Rho pathway by lysophosphatidic acid results in growth cone collapse and eventually to neurite retraction. Finally, we show that blocking of Rho kinase, but not RhoA results in an increase in neurons bearing neurites. Due to its anti-inflammatory and neurite growth promoting action, the use of a pharmacological treatment of damaged neural tissue with Ibuprofen should be explored.

Introduction

In general, the adult mammalian central nervous system (CNS) cannot regenerate injured axons. As a consequence, human patients with severe spinal cord injuries suffer from loss of motor control and sensation. The reasons for the inability to regenerate fall into two broad categories: the non-permissive tissue environment and neuron intrinsic factors [1]. Main obstacles in the neuronal environment are reactive astrocytes that generate chondroitin sulfate
proteoglycans (CSPGs) forming scar tissue [2,3] and myelin-producing oligodendrocytes that expose myelin associated glycoprotein (MAG), Nogo-A [4] and oligodendrocyte myelin glycoprotein (OMgp) as growth-inhibitory factors [5–8] to the axons. These two broad classes of molecules are upregulated after neuronal injury and prevent regeneration beyond the lesion site. All of the mentioned extracellular growth inhibiting factors interact with various receptors on the axonal membrane and converge downstream on the small GTPase RhoA signaling pathway [8]. The activation of RhoA causes cytoskeletal changes eventually leading to a growth cone collapse which in turn suppresses axonal re-extension [9].

A rather promising approach for enabling axonal regeneration is the chemical manipulation of the Rho signaling cascade [8, 10–13]. In vitro and in vivo studies using rodents have shown that inhibition of Rho activation resulted in neurite outgrowth on non-permissive myelin and CSPG substrates and in improved sprouting of serotonin-positive fibers across the lesion site [11,13–16]. Moreover, blocking the downstream effector of RhoA, the Rho kinase (ROCK, Rho-associated coiled coil forming protein serine/threonine kinase) increased axonal regeneration in cultures of embryonic and adult rat neurons [11,17]. Non-steroid anti-inflammatory drugs (NSAIDs), such as ibuprofen do not only target cyclooxygenases, but suppress also Rho-A activation [18]. Translation of the neurite growth promoting effect of Rho manipulation into a therapeutic treatment of axonal damage requires testing of pharmaceutical agents not only in experimental animals, but also on human neurons. Several inhibitors of ROCK have been shown to partially restore neurite outgrowth of human (NT2, Ntera2, NT2/D1 precursor cells) neurons on non-permissive CSPG substrate [15].

Here, we investigated for the first time whether the analgetic Ibuprofen could enhance neurite outgrowth of human neurons on a permissive substrate. These model neurons were differentiated by retinoic acid treatment from the Ntera2/D1 clone of a human teratocarcina line [19] and have been well characterized in a variety of biomedical applications [20] including neurite outgrowth assays [15,21,22]. We asked whether a blocker (Y-27632, (1R,4r)-4-((R)-1-aminoethyl)-N-(pyridin-4-yl)cyclohexanecarboxamide) of ROCK activation, the other downstream therapeutic target, would affect neurite outgrowth with comparable efficacy. After treating the human model neurons with Ibuprofen, levels of RhoA activity were determined in a pull down assay. Since Rho/ROCK inhibition is known to change cytoskeletal dynamics, we compared the capability of the human neurons for neurite initiation under RhoA and ROCK inhibiting conditions.

Materials and Methods

Antibodies and reagents

Unless stated otherwise, all chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany). All test substances were diluted in Dulbecco’s modified eagle medium nutrient mixture F-12 (DMEM/F12, Gibco-Invitrogen, Karlsruhe, Germany) containing 10% fetal bovine serum (Gibco-Invitrogen), 1% Penicillin and Streptomycin (Gibco-Invitrogen) and 10 μM retinoic acid. The non-steroidal cyclooxygenase inhibitor Ibuprofen, the ROCK inhibitors Y-27632 and Fasudil, and the cAMP analogue 8-Br-cAMP (8-Bromoadenosine 3',5'-cyclic monophosphate) were purchased from Sigma-Aldrich. The RhoA Activation Assay Biochem Kit (bead pull-down format) was purchased from Cytoskeleton Inc. (Denver, CO, USA). Alamar Blue cell viability assay to measure cytotoxic effect was purchased from Trinova (Giessen, Germany).

Neuronal differentiation

Human NT2/D1 precursor cells (NT2) were purchased from the American Type Culture Collection (ATTC, Manassas, VA, USA). Neuronal differentiation was carried out as previously described [21]. NT2 precursor cells were cultured in 95 mm bacteriological grade Petri dishes
Cultures in each Petri dish had at least densities of 5 x 10^6 cells/dish in 10 ml DMEM/F12 supplemented with 10% fetal bovine serum, 1% Penicillin and Streptomycin and 10 μM retinoic acid (RA medium) to start neuronal differentiation. Cells were cultured for 14 days in RA medium in a free floating sphere culture with medium change every 2–3 days. At the end of the incubation, cells were centrifuged, mechanically dispersed and counted. Dispersed cells were seeded to poly-D-lysine (10 μg/ml, Sigma-Aldrich) and Laminin (100 μg/ml, Sigma-Aldrich) coated 96-well-plates (Corning Costar, Kaiserslautern, Germany) at a density of 10,000 cells per well and with 8 wells per concentration. Experiments were performed with neurons treated for two weeks with retinoic acid (2wkRA) from passage 27 to 35.

Neurite outgrowth assay
After cells had successfully attached to the plate, RA medium was changed against RA medium containing the test substances. Ibuprofen (10, 100, 500 μM) and 8-Br-cAMP (1 mM) were dissolved in RA medium. The ROCK inhibitor Y-27632 (1, 5, 10, 50 μM) was diluted to final concentration from a stock solution (10 mM) in H2O. The ROCK inhibitor Fasudil was diluted in culture media to final concentrations of 1 μM, 10 μM, and 100 μM. Cells were cultured for 24 hours under standard conditions (37°C, 5% CO₂) in an incubator. Each experiment was performed in 8 wells per concentration/substance and was repeated at least 3 times. The next day, cells were washed with PBS (phosphate buffered saline) and subjected to the Alamar Blue cell viability assay to measure possible cytotoxic side effects.

Cell viability assay / Toxicity assay
Survival of cells after treatment with Ibuprofen, Y-27632, Fasudil, and 8-Br-cAMP was quantified using the Alamar Blue cell viability assay. Cultures were incubated under standard conditions (37°C, 5% CO₂) in 200 μl RA-medium and with 5% Alamar Blue for two hours. Alamar Blue fluorescence was measured for each well using a plate reader (Infinite M200, Tecan, Mainz, Germany) with an excitation wavelength of 560 nm and an emission wavelength of 590 nm at 37°C. Basal fluorescence of Alamar Blue solution was subtracted as blank from relative fluorescence values. Survival rate was calculated and standardized based on the means of control wells. For all used concentrations of the pharmacological agents, we found no significant decrease in viability.

Immunocytochemistry
Stainings were performed as described earlier [21,22]. Cultures were rinsed with PBS to remove remaining Alamar Blue solution. Cells were then fixed with 4% PFA (paraformaldehyde) for 15 minutes at room temperature and washed 3 times in PBS containing 0.1% Triton X-100 (PBST) to remove remaining PFA. Unspecific protein binding sites were blocked with 5% normal horse serum in PBST for at least 60 minutes at room temperature. Monoclonal antibody β-III-Tubulin (1:10,000, Sigma) was applied overnight at 4°C. After 3 washing steps in PBST, neurons were incubated with biotinylated secondary antibody horse-against mouse (Vector, Burlingame, MA, USA) for 60 minutes at room temperature before 3 additional washing steps in PBST. Streptavidin coupled Cy3 was applied for 60 minutes at room temperature to detect immunofluorescence. To visualize nuclei we used DAPI (4’6-diamidino-2’henylindoldihydrochloride) at a concentration of 0.1 μg/ml as a counterstain.

RhoA pull down assay
For detection of RhoA, we performed a RhoA pull down assay (Cytoskeleton, Denver, CO, USA). Lysates were collected from cells differentiated under control conditions or
inhibition of RhoA and ROCK via Ibuprofen and Y-27632 respectively. Cells were cultured for 30 minutes (37°C, 5% CO2) on PDL and Laminin coated bacteriological 35 mm petri dishes (Falcon) at a density of 2x10^6 cells. For lysate collection, cells were washed with ice cold PBS and then lysed in ice cold lysis puffer for 1 min. The lysate were centrifuged for 1 min at 4°C and 10,000g. The supernatants were snap frozen in liquid nitrogen and kept in a freezer until use in the pull down assay. Total protein quantification was performed with the Pierce BCA Protein Assay Kit (Thermo Scientific) and a plate reader (Infinite M200, Tecan). The RhoA pull down was performed according the manufacturer’s instructions. The cell lysates were incubated with Rhotekin-RBD beads at 4°C for at 60 min on a rocker. After centrifugation (5,000g for 1 min) at 4°C, the supernatant was nearly completely removed. After washing in wash buffer the remaining lysate was centrifuged again (5,000g for 1 min at 4°C).

**Western blotting**

Prior to SDS-PAGE, 300 μg protein samples from the pull down assay were denatured at 95°C for 2 minutes in loading buffer (2× Laemmli buffer with 2% SDS, 10% 1 M Dithiothreitol). Samples were transferred to a precast 10% Tris-Glycine gel (NuSep, Wasserburg, Germany) and ran until the dye front reached the end of the gel. After equilibration of the gel in western blot buffer, the protein was transferred to a PVDF membrane. After blocking with 5% nonfat-dry milk in Tris Buffered Saline with Tween (TBST), RhoA was detected with the anti-RhoA (1:500 in TBST). Detection of the primary antibody was performed with a goat anti-mouse antibody (1:20,000) conjugated with biotin. The Vectastain ABC Kit (Vectorlabs, Peterborough, UK) was applied as recommended by the manufacturer for 30 minutes after 3 preceding wash steps with TBST. The bound biotin-avidin complex was visualized using the DAB peroxidase substrate kit (Vectorlabs). A brownish to black staining became visible after 10 minutes incubation. The reaction was stopped in distilled water. Using the open source tool ImageJ 1.47 (http://rsbweb.nih.gov/ij/), scanned blots were converted to inverted 8 bit grey scale images and analyzed with the ImageJ integrated gel analyze plugin. Grey values were normalized using the “sum of all data points in a replicate” according to Degasperi et al. 2014 [23].

**Microscopy and statistical analysis**

Fluorescence images were taken with a Zeiss Axiovert 200 (Jena, Germany). The microscope was equipped with a CoolSnap camera (Photometrics, Tucson, AZ, USA) and MetaMorph software (Molecular Devices, Sunnyvale, CA, USA). Length of neurites was measured using the open source software of the NIH ImageJ 1.46d (Rasband W.S., ImageJ, U.S. National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/). The longest neurite of a neuron was measured from the soma to the tip. Additionally, the number of neurites for each neuron was counted and saved for later evaluation. Merging of channels, adjustment of contrast and brightness and addition of a scale bar were performed with ImageJ. Images were arranged with the GNU licensed layout tool Scribus 1.4.3. Statistical analysis was performed with Graph Pad Prism 5.0.1. Data are expressed as the mean ± SEM of at least 3 independent experiments. Data were analyzed according Gaussian distribution. If the data passed the normality test, significant differences were determined by ANOVA. Otherwise the data were analyzed with the Kruskal-Wallis-test with a Dunn’s post hoc test. Neurite outgrowth experiments were performed with 8 wells per concentration in at least 3 independent experiments. Significant levels are **=<0.05, ***=<0.01, ****=<0.001.
Results

RhoA/ROCK inhibition promotes neurite elongation of human neurons

Culturing human NT2 2wkRA neurons with Ibuprofen resulted in an increased length of the longest neurite to 114.0% of control at 100 μM (Fig. 1A and F) and 132.2% of control at 500 μM (Fig. 1A and G). Lower concentrations (10 μM) failed to increase neurite length in a significant way (Fig. 1A and E). Moreover, we used a membrane permeable cAMP analogue to elevate intracellular levels of cAMP. Incubation with 1 mM 8-Br-cAMP resulted in a less, but still significant elongation of neurites to 121% of control (Fig. 1B and D).

Culturing the 2wkRA neurons with an inhibitor for the downstream effector of RhoA, the Rho Kinase resulted also in significantly longer neurites. Even low concentrations of 1 μM of the ROCK inhibitor Y-27632 caused an elongation to 129% of control (Fig. 2A), the level reached by application of 500 μM Ibuprofen (Fig. 1A and C). The dose dependent effect of Y-27632 showed an increased elongation to 150% of control at 5 μM (Fig. 2A and D), 170% of control at 10 μM (Fig. 2A and E), and a doubling to 202% of control at the highest Y-27632 concentration used (50 μM, Y-27632, Fig. 2A and F). To obtain independent support for the strategy of neurite growth enhancement by RhoA/ROCK inhibition, we used a second ROCK blocker. Treatment with the ROCK inhibitor Fasudil led to a similar increase in neurite lengths as seen for Y-27632 (Fig. 2B).

The increase in neurite lengths was highly significant for Fasudil levels of 10 μM and 100 μM.

Inhibition of RhoA/ROCK facilitates neurite initiation

In an attempt to test whether RhoA/ROCK inhibition directly effects elongation of existing neurites or whether the initiation of new neurites is altered, we categorized β-tubulin III-positive cells into neurons with and without neurites. Under control conditions, approximately 60% of the neurons had grown at least one neurite (Fig. 3). Culturing neurons for 24 hours under Ibuprofen treatment resulted in a dose dependent increase from 57.52% at 10 μM, 67.85% at 100 μM, and to 75.62% at 500 μM Ibuprofen (Fig. 3A). However, only at the highest applied Ibuprofen concentration of 500 μM we obtained statistical significance. Culturing neurons under elevated levels of cAMP resulted in a weak but not significant increase of neurite bearing cells to 65.77% of β-tubulin III-positive cells (Fig. 1B). Application of the ROCK inhibitor Y-27632 led to increased neurite formation shown as a dose dependent increase of neurite bearing cells (Fig. 3C). Under control conditions approximately 67% of all cells generated a neurite. After application of Y-27632, the percentage increased in a dose dependent manner to 86% at 50 μM Y-27632, which was significantly different from control. Application of the ROCK inhibitor Fasudil led to an increase in neurite bearing cells to approximately 75% at 100 μM (Fig. 3D).

Activation of RhoA results in growth cone collapse and neurite retraction

Inhibition of RhoA and Rho kinases resulted in enhanced neurite outgrowth compared to control conditions. We tested whether a potent RhoA activator, such as lysophosphatidic acid (LPA) had the opposite effect leading to decreased neurite lengths. After 24 hours incubation with LPA, neurite lengths did not differ from control (Fig. 4). Neurite lengths ranged from 103.5±4.5 percent of control at 1 μM LPA to 104.3±4.9 percent of control at 10 μM LPA. Neurons cultured with 500 μM Ibuprofen on the same cell culture plate showed a mean neurite length of 138.5±4.9 percent of control (Fig. 4).

We further checked whether RhoA activation could change shape and motility of growth cones on a shorter time scale. Culturing neurons with 10 μM LPA initially resulted in a broad growth cone collapse and neurite retraction within 45 minutes while growth cones under control conditions showed no reaction (Fig. 4B, D). On average, LPA administration caused a...
Fig 1. Ibuprofen increased neurite length of human model neurons. (A) Treatment with 100 μM and 500 μM Ibuprofen increased neurite outgrowth of human model neurons as measured after 24 hours. At 10 μM Ibuprofen treatment no difference to control could be detected. In 4 independent experiments, 778 to 2361 neurites were measured in total. (B) Neurite elongation under Ibuprofen treatment was slightly higher than in neurons treated with the membrane permeable analogue 8-Br-cAMP (5 experiments, 1015 to 2030 neurites measured. (C) Immunofluorescence staining of human model neurons under control conditions. (D) Neurons treated with 1 mM 8-Br-cAMP. (E-G) Neurons treated with 10 μM (E), 100 μM (F) and 500 μM (G) Ibuprofen. Cells are stained against beta-III-tubulin and counterstained with DAPI. **p<0.001 with control by Kruskal-Wallis one-way ANOVA. Scale bars are 50 μm.

doi:10.1371/journal.pone.0118536.g001
neurite retraction for about 65 μm over 45 minutes. Treatment with Ibuprofen induced no conspicuous effect on growth cone shape and behavior within this time interval (Fig. 4C).

Next, we measured the abundance of active RhoA in human model neurons under activating and inhibiting conditions in a pull down assay. Culturing neurons for 30 min with the Rho activator LPA caused an increased level of RhoA (Fig. 5). While the inhibitor Ibuprofen brought RhoA levels down to approximately 50% of control, incubation with the downstream Rho kinase inhibitor Y-27632 and Fasudil showed no effects on the level of activated RhoA.

Discussion

Major obstacles for axonal regeneration after CNS injury are myelin-associated proteins, causing growth cone collapse and the formation of a glial scar, acting as physical barrier and containing growth-inhibitory proteoglycans [3]. For example, in spinal cord injury (SCI) the formation of the glial scar requires several weeks. This would enable at least a theoretical time window for axonal regeneration beyond the forming glial scar [24], if the growth-inhibitory environment of the myelin could be neutralized. Nevertheless, a remaining problem for functional recovery from CNS injuries is the long distance that some axons have to cover to reconnect to their synaptic targets. For developing therapeutic treatments, it would be necessary to provide an enhanced capability for outgrowth to the severed axons. Using human NT2 neurons in an in vitro assay, we have previously shown that the cAMP/PKA (protein kinase A, cAMP-
dependent kinase) pathway [21] and co-culture with olfactory ensheathing cells [22] enhance the capability for neurite outgrowth. In this investigation, we focused on the Rho/ROCK pathway because it integrates many extracellular growth inhibitory signals of the CNS tissue [18], serving as a key regulator of the axonal growth state.

Ibuprofen and Y-27632 enhance neurite length of human model neurons

In vitro treatment of human model neuron cultures with Ibuprofen increased neurite length to a similar extent as elevating cAMP levels (Fig. 1A, B). Moreover, using the ROCK blocker Y-27632, we found an almost two fold enhancement of neurite length (Fig. 2). Most likely, the effects on neurite length of both compounds are mediated via their inhibitory action on the RhoA/ROCK pathway [18,25]. The pull down assay (Fig. 5) showed indeed that treatment of NT2 neurons with Ibuprofen decreased RhoA activation, while LPA, a stimulator of the Rho pathway increased activation. Both downstream ROCK blockers Y-27632 and Fasudil showed no effect.

Fig 3. RhoA and Rho kinase inhibitors promote initiation of neurites. (A) The percentage of cells bearing a neurite was significantly increased at 500 μM of Ibuprofen whereas 10 μM and 100 μM led to no difference to control conditions (3–7 independent experiments, 744 to 2358 neurites measured). (B) Application of cAMP did not change the number of cells bearing a neurite, however neurite lengths were increased to a similar amount compared to Ibuprofen (5 independent experiments, 1151 to 1775 neurites measured). (C) Blocking Rho kinases with increasing levels of Y-27632 resulted in a trend to more cells bearing a neurite. A highly significant effect was observed at 50 μM (3 independent experiments, 732 to 973 neurites measured). (D) Blocking Rho kinases with elevated levels of Fasudil (100 μM) resulted in a highly significant increase in neurite bearing cells (3 independent experiments, 1857 to 3422 neurites measured). **p<0.01 and *p<0.05 against control by Kruskal-Wallis test.

doi:10.1371/journal.pone.0118536.g003
Inhibitors of Rho/ROCK Signaling Enhance Neurite Growth

Fig 4. Rho activation resulted in a growth cone collapse, but not decreased neurite lengths. (A) Measurements of neurite outgrowth after 24 h incubation with elevated levels of the Rho activator lysophosphatidic acid (LPA) showed no change in neurite lengths, whereas Ibuprofen increased neurite length (2 independent experiments, 470 to 947 neurites measured). (B) Within 45 min, neurons cultured under control conditions showed a slowly advancing growth cone. (C) Inhibition of RhoA using 500 μM
The positive effects on neurite lengths after RhoA/ROCK inhibition are in line with several functional regeneration studies after spinal cord hemisection described in a systematic review. Pharmacological intervention causing blockage of RhoA/ROCK resulted in an overall increase to 15% in locomotor activity [26]. Human NT2 neurons have been reported as very susceptible to the RhoA activating chondroitin sulphate proteoglycans (CSPG) in vitro [15]. Grown on a CSPG substrate, they failed to grow neurites and neurite length was decreased to 20% of control. Blocking of RhoA with Fasudil prevented the CSPG mediated inhibitory effect at least partially [15]. Fasudil treatment rescued neurite lengths to 70% of control. In the present investigation, we cultured human 2wkRA neurons on a permissive substrate with concentrations of the analgetic Ibuprofen, which has also been discovered to block RhoA activation [18,25]. After 24 hours

Ibuprofen elicited a weak positive effect on filopodial formation and extension of growth cone. (D) RhoA activation using 100 μM LPA resulted in a growth cone collapse and retraction of the neurite. **p < 0.001 against control by Kruskal-Wallis. Scale bar is 25 μm.

doi:10.1371/journal.pone.0118536.g004

![Fig 5. Pull down assay of RhoA.](image)

(A) A RhoA bead pull down assay revealed lowered levels of activated RhoA in Ibuprofen treated cells. Treatment with downstream Rho kinase inhibitor Y-27632 showed no difference in RhoA level compared to control. After treatment with lysosphatidic acid, significantly more phosphorylated RhoA could be detected in the Western Blot. Treatment with downstream Rho kinase inhibitor Fasudil showed no difference in RhoA level compared to control. Cell lysates were blotted and stained with RhoA-specific monoclonal antibody. Staining is visualized with horseradish peroxidase and the 3, 3′-diaminobenzidine substrate. Molecular weight of stained protein bands corresponds to about 20 kDa as reported for RhoA. (B) Relative RhoA level was decreased to approximately 50% of control after Ibuprofen treatment whereas RhoA level after LPA treatment was increased to 200% of control. Data are normalized grey values ± SEM of 4 independent experiments.

doi:10.1371/journal.pone.0118536.g005
Ibuprofen treatment, neurite lengths were increased. Thus, we show to our knowledge for the first time an increase in neurite outgrowth of human neurons on a permissive substrate by RhoA/ROCK inhibiting agents (Figs. 1 and 2). Similar results after inhibition of RhoA have been found in SCI models of adult mice [14] retinal nerve, and thoracic spinal cord transection injury models of rats [25,27]. Subcutaneous administration of 60 mg/kg Ibuprofen per day resulted in rostral sprouting of corticospinal tract fibers [25]. Culturing rat pheochromocytoma neurons (PC12) with the RhoA activating agent LPA resulted in dramatically increased RhoA levels in vitro [25] Ibuprofen and indomethacin prevented this increase. Moreover, PC12 neurons exposed to myelin led to high levels of RhoA in cell lysates whereas treatment with Ibuprofen abolished this increase [25]. Since several studies suggested treatment with ROCK inhibitors as a promising therapy to treat spinal cord injuries [8,10,28,29], we tested whether the Rho kinase inhibitor Y-27632 could promote neurite outgrowth and elongation in similar manner as Ibuprofen does. Inhibition of Rho kinase, a downstream target of RhoA, indeed led to a dose-dependent increase (Fig. 2) of neurite lengths in vitro. This result confirmed the increased neurite elongation observed in neurons derived from mouse neural stem cells after Y-27632 treatment [13].

Increased RhoA levels after LPA treatment had no significant impact on long-term neurite outgrowth (Fig. 4). However, activation of RhoA by LPA resulted in a complete growth cone collapse and rapid neurite retraction within the time frame of 45 minutes (Fig. D, D’).

In comparison to earlier studies using human NT2 neurons [15], we demonstrated the neurite outgrowth enhancing effects of Ibuprofen and Y-27632 for human model neurons on a permissive substrate. Such findings might be important for regeneration in the peripheral nervous system, where axon outgrowth is not impaired by such a hostile environment as in the central nervous system [30,31].

Rather, for peripheral nervous system regeneration the time frame in which axons re-establish contact to distal nerve stumps is of more importance [32–34]. Within several days and weeks after transection or avulsion of ventral roots, extensive death of motor neurons of 50–80% occurred [35–38]. For humans, the gold standard for peripheral nerve repair is the transplantation of autologous scaffolds with moderate regeneration over nerve gaps not wider than 20 mm [39]. Levels of mRNA of RhoA were increased in injured rat DRG neurons [34]. Neurite lengths in vitro and an increase of number of axons in vivo were the results after application of the RhoA-ROCK inhibitor HA-1077 [34]. Here we show similar results in human model neurons as reported for rat DRG neurons [34] Application of Ibuprofen to PNS injuries may result in the bridging of longer nerve defects and a faster regeneration process with less or absent degeneration of nerve stumps.

Earlier studies in our laboratory have shown the effect of the cAMP pathway on neurite outgrowth in human NT2 neurons. Exogenously applied cAMP or treatment with the adenylyl cyclase activator, Forskolin, resulted in an increase of neurite extension to 150% of control [21]. Here we report that treatment with Ibuprofen increased lengths of neurites to a similar extent. This could be explained by earlier studies showing Rho inhibition via cAMP [40–42]. The cAMP-dependent kinase (PKA) phosphorylates RhoA, resulting in a translocation of membrane-bound RhoA to the cytosol and therefore a loss of function for RhoA.

Inhibition of RhoA/ROCK induces neurite formation

Initiation and formation of neurites by severed neurons is a prerequisite for regeneration mechanisms [43]. Therefore we counted the number of neurites of human 2wkRA neurons cultured in RhoA-inhibiting Ibuprofen and ROCK-inhibiting Y-27632. Ibuprofen and Y-27632 incubation resulted in more neurons bearing neurites (Fig. 3). Inhibition of Rho kinases with Y-27632 resulted in a decrease of myristoylated alanine-rich C kinase substrate (MARCKS) in human SH-SY5Y cells [44]. Expression of an unphosphorylatable mutant of MARCKS also led
to an increase in neurite bearing cells. This effect could also be elicited by treatment with the insulin-like growth factor-1 (IGF-1) inducing a transient inactivation of RhoA [44]. In line with these results, neurite initiation was prevented after RhoA and ROCK activation [45]. Decreased RhoA activity on PC12 cells was observed after treatment with nerve growth factor (NGF), a major trigger for neuritogenesis of this cell line [46]. Treatment of CA1/CA3 hippocampal neurons of mice with Rho and ROCK inhibitors caused also neurite initiation [47].

In summary, here we showed for the first time that treatment of human neurons with a commercial pain reliever enhanced the neurite growth capacity. These encouraging in vitro results are in line with findings in experimental animals, showing that inhibition of RhoA-ROCK overcomes the regeneration inhibitory effects of myelin and chondroitin sulfate proteoglycans. Blocking of a single signal transduction pathway is rather unlikely to fully account for neurite regeneration. Since Ibuprofen additionally attenuates the inflammatory response caused by injury, therapeutic strategies [48,49] for the application of the drug close to the site of neural tissue damage should be explored.

Acknowledgments
We like to thank Saime Tan for assistance in the cell lab.

Author Contributions
Conceived and designed the experiments: FR MS GB. Performed the experiments: FR CD HS SD. Analyzed the data: FR CD. Contributed reagents/materials/analysis tools: GB. Wrote the paper: FR CD GB. Read and approved the final manuscript: FR HS CD SD MS GB.

References
1. Benowitz LI, Yin Y. Combinatorial treatments for promoting axon regeneration in the CNS: strategies for overcoming inhibitory signals and activating neurons’ intrinsic growth state. Dev Neurobiol. 2007; 67:1148–1165. doi: 10.1002/dneu.20515 PMID: 17514713
2. Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002; 416:636–640. doi: 10.1038/416636a PMID: 11948352
3. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004; 5:146–156. doi: 10.1038/nrn1326 PMID: 14735117
4. Schwab ME. Nogo and axon regeneration. Curr Opin Neurobiol. 2004; 14:118–124. doi: 10.1016/j.conb.2004.01.004 PMID: 15018947
5. Aguayo AJ, David S, Bray GM. Influences of the glial environment on the elongation of axons after injury: transplantation studies in adult rodents. J Exp Biol. 1981; 95:231–240. PMID: 7334319
6. Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci. 2003; 4:703–713. doi: 10.1038/nrn1195 PMID: 12951563
7. McGee AW, Strittmatter SM. The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci. 2003; 26:193–198. doi: 10.1016/S0166-2236(03)00062-6 PMID: 12889770
8. Tönges L, Koch J-C, Bähr M, Lingor P. ROCKing Regeneration: Rho Kinase Inhibition as Molecular Target for Neurorestoration. Front Mol Neurosci. 2011; 4:39. doi: 10.3389/fnmol.2011.00039 PMID: 22065949
9. Gallo G, Letourneau PC. Regulation of growth cone actin filaments by guidance cues, J Neurobiol. 2004; 58:92–102. doi: 10.1002/neu.10282 PMID: 14598373
10. Wu D, Yang P, Zhang X, Luo J, Haque ME, Yeh J, et al. Targeting a dominant negative rho kinase to neurons promotes axonal outgrowth and partial functional recovery after rat rubrospinal tract lesion. Mol Ther. 2009; 17:2020–2030. doi: 10.1038/mt.2009.168 PMID: 19623163
11. Boomkamp SD, Riehle MO, Wood J, Olson MF, Barnett SC. The development of a rat in vitro model of spinal cord injury demonstrating the additive effects of Rho and ROCK inhibitors on neurite outgrowth and myelination. Glia. 2012; 60:441–456. doi: 10.1002/glia.22276 PMID: 22139636
12. DeGeer J, Lamarche-Vane N. Rho GTPases in neurodegeneration diseases. Exp Cell Res. 2013; 319:2384–2394. doi: 10.1016/j.yexcr.2013.06.016 PMID: 23830879

13. Gu H, Yu SP, Gutekunst C-A, Gross RE, Wei L. Inhibition of the Rho signaling pathway improves neurite outgrowth and neuronal differentiation of mouse neural stem cells. Int J Physiol Pathophysiolog Pharmacol. 2013; 5:11–20. PMID: 23525456

14. Dergham P, Ellezam B, Essajian C, Avedissian H, Lubell WD, McKerracher L. Rho signaling pathway targeted to promote spinal cord repair. J Neurosci. 2002; 22:6570–6577. doi: 20026637 PMID: 12151736

15. Lingor P, Teusch N, Schwarz K, Mueller R, Mack H, Bähr M, et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem. 2007; 103:181–189. doi: 10.1111/j.1471-4159.2007.04756.x PMID: 17608642

16. Wang X, Budel S, Baughman K, Gould G, Song K-H, Strittmatter SM. Ibuprofen enhances recovery from spinal cord injury by limiting tissue loss and stimulating axonal growth. J Neurotrauma. 2009; 26:81–95. doi: 10.1089/neu.2007.0464 PMID: 19125588

17. Fournier AE, Takizawa BT, Strittmatter SM. Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci. 2003; 23:1416–1423. PMID: 12598630

18. Kopp MA, Liembser T, Niedeggen A, Laufser S, Brommer B, Junghelusing GJ, et al. Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury. Cell Tissue Res. 2012; 349:119–132. doi: 10.1007/s00441-012-1334-7 PMID: 22350947

19. Andrews PW, Damjanov I, Simon D, Banting GS, Carlin C, Dracopoli NC, et al. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Lab Invest. 1984; 50:147–162. PMID: 6694356

20. Paquet-Durand F, Bicker G. Human model neurons in studies of brain cell damage and neural repair. Curr Mol Med. 2007; 7:541–554. PMID: 17896991

21. Tegenge MA, Roloff F, Bicker G. Rapid differentiation of human embryonal carcinoma stem cells (NT2) into neurons for neurite outgrowth analysis. Cell Mol Neurobiol. 2011; 31:635–643. doi: 10.1007/s10571-011-9659-4 PMID: 21331625

22. Roloff F, Ziege S, Baumgärtner W, Wewetzer K, Bicker G. Schwann cell-free adult canine olfactory en- sheathing cell preparations from olfactory bulb and mucosa display differential migratory and neurite growth-promoting properties in vitro. BMC Neurosci. 2013; 14:141. doi: 10.1186/1471–2202–14–141 PMID: 24219805

23. Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN. Evaluating strategies to normalise biological replicates of Western blot data. PLoS ONE. 2014; 9:e87293. doi: 10.1371/journal.pone.0087293 PMID: 24475266

24. Hu R, Zhou J, Luo C, Lin J, Wang X, Li X, et al. Glial scar and neuroregeneration: histological, functional, and magnetic resonance imaging analysis in chronic spinal cord injury. J Neurosurg Spine. 2010; 13:169–180. doi: 10.3171/2010.3.SPINE09190 PMID: 20672952

25. Fu Q, He J, Li S. Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. J Neurosci. 2007; 27:4154–4164. doi: 10.1523/JNEUROSCI.4353–06.2007 PMID: 17428993

26. Watzlawick R, Sena ES, Dimagli U, Brommer B, Kopp MA, Macleod MR, et al. Effect and reporting bias of RhoA/ROCK-blockade intervention on locomotor recovery after spinal cord injury: a systematic review and meta-analysis. JAMA Neurol. 2014; 71:91–99. doi: 10.1001/jamaneurol.2013.4684 PMID: 24297045

27. Ellezam B, Dubreuil C, Winton M, Loy L, Dergham P, Sellès-Navarro I, et al. Inactivation of intracellular Rho to stimulate axon growth and regeneration. Prog Brain Res. 2002; 137:371–380. PMID: 12440379

28. Kubo T, Hata K, Yamaguchi A, Yamashita T. Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration. Curr Pharm Des. 2007; 13:2493–2499. PMID: 17692017

29. Lingor P, Tönges L, Pieper N, Barski E, Planchamp V, et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal gangli-on cells. Brain. 2008; 131:250–263. doi: 10.1093/brain/awm284 PMID: 18063589

30. Radtke C, Vogt PM. Peripheral nerve regeneration: a current perspective. Eplasty. 2009; 5:e47. PMID: 19907643

31. Gao X, Wang Y, Chen J, Peng J. The role of peripheral nerve ECM components in the tissue engineering nerve construction. Rev Neurosci. 2013; 24:443–453. doi: 10.1515/revneuro-2013–0022 PMID: 23907421

32. Archibald SJ, Sheflner J, Krarup C, Madison RD. Monkey median nerve repaired by nerve graft or colla- gen nerve guide tube. J Neurosci. 1995; 15:4109–4123. PMID: 7751969
33. McDonald D, Cheng C, Chen Y, Zoehdne D. Early events of peripheral nerve regeneration. Neuron Glia Biol. 2006; 2:139–147. doi: 10.1017/S1740925X05000347 PMID: 18634586

34. Cheng C, Webber CA, Wang J, Xu Y, Martinez JA, Liu WQ, et al. Activated RHOA and peripheral axon regeneration. Experimental Neurology. 2008; 212:358–369. doi: 10.1016/j.expneurol.2008.04.023 PMID: 18554585

35. Koliatsos VE, Price WL, Pardo CA, Price DL. Ventral root avulsion: an experimental model of death of adult motor neurons. J Comp Neurol. 1994; 342:35–44. doi: 10.1002/cne.903420105 PMID: 8207127

36. Martin LJ, Kaiser A, Price AC. Motor neuron degeneration after sciatic nerve avulsion in adult rat evolves with oxidative stress and is apoptosis. J Neurobiol. 1999; 40:185–201. PMID: 10413449

37. Natsume A, Mata M, Wolfe D, Oligno T, Goss J, Huang S, et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect. J Neurotrauma. 2002; 19:61–68. doi: 10.1089/089771502753460240 PMID: 11852979

38. Hoang TX, Nieto JH, Tillakaratne NJK, Havton LA. Autonomic and motor neuron death is progressive and parallel in a lumbar-sacral ventral root avulsion model of cauda equina injury. J Comp Neurol. 2003; 467:477–486. doi: 10.1002/cne.10928 PMID: 14624482

39. Reyes O, Sosa I, Kuffler DP. Promoting neurological recovery following a traumatic peripheral nerve injury. P R Health Sci J. 2005; 24:215–223. PMID: 16329686

40. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 1996; 15:510–519. PMID: 8599934

41. Dong JM, Leung T, Manser E, Lim L. cAMP-induced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROKalpha. J Biol Chem. 1998; 273:22554–22562. PMID: 9712882

42. Sebök A, Nusser N, Debreceni B, Guo Z, Santos MF, Széberenyi J, et al. Different roles for RhoA during neurite initiation, elongation, and regeneration in PC12 cells. J Neurochem. 1999; 73:949–960. PMID: 10461884

43. Flynn KC. The cytoskeleton and neurite initiation. Bioarchitecture. 2013;3.

44. Shiraishi M, Tanabe A, Saito N, Sasaki Y. Unphosphorylated MARCKS is involved in neurite initiation induced by insulin-like growth factor-I in SH-SY5Y cells. J Cell Physiol. 2006; 209:1029–1038. doi: 10.1002/jcp.20814 PMID: 16941462

45. Hirose M, Ishizaki T, Watanabe N, Uehata M, Kranenburg O, Moolenaar WH, et al. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol. 1998; 141:1625–1636. PMID: 9647654

46. Yamaguchi Y, Katoh H, Yasui H, Mori K, Negishi M. RhoA inhibits the nerve growth factor-induced Rac1 activation through Rho-associated kinase-dependent pathway. J Biol Chem. 2001; 276:18977–18983. doi: 10.1074/jbc.M100264200 PMID: 11279039

47. Bitó H, Furuyashiki T, Ishihara H, Shibasaki Y, Ohashi K, Mizuno K, et al. A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons. Neuron. 2000; 26:431–441. PMID: 10839361

48. Carafa M, Marianecce C, Di Marzio L, Rinaldi F, Meo C, Matricardi P, et al. A new vesicle-loaded hydrogel system suitable for topical applications: preparation and characterization. J Pharm Pharm Sci. 2011; 14:336–346. PMID: 21900319

49. Hu X, Wang N, Liu L, Liu W. Cyclodextrin-cross-linked diaminotriazine-based hydrogen bonding strengthened hydrogels for drug and reverse gene delivery. J Biomater Sci Polym Ed. 2013; 24:1869–1882. doi: 10.1080/08975003.2013.808150 PMID: 23862984